These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 35686412)

  • 1. Neoadjuvant Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.
    Xue C; Dong H; Chen Y; Lu X; Zheng S; Cui H
    J Coll Physicians Surg Pak; 2022 Jun; 32(6):779-788. PubMed ID: 35686412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Meta-Analysis of Efficacy and Safety of Neoadjuvant Immunotherapy Plus Chemotherapy for Resectable Non-Small Cell Lung Cancer.
    Sun X; Kang T; Liu B; Zhang Y; Huang G
    Clin Respir J; 2024 Oct; 18(10):e70019. PubMed ID: 39359047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review.
    Ulas EB; Dickhoff C; Schneiders FL; Senan S; Bahce I
    ESMO Open; 2021 Oct; 6(5):100244. PubMed ID: 34479033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitors in neoadjuvant therapy of non-small cell lung cancer: a systematic review and meta-analysis.
    Ge S; Huang C
    J Thorac Dis; 2022 Feb; 14(2):333-342. PubMed ID: 35280480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The optimal immune checkpoint inhibitors combined with chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis.
    Yang Y; Luo H; Zheng XL; Ge H
    Clin Transl Oncol; 2021 Jun; 23(6):1117-1127. PubMed ID: 33211281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review and meta-analysis of neoadjuvant chemoimmunotherapy in stage III non-small cell lung cancer.
    Liu W; Zhang T; Zhang Q; Li L; Xu C
    BMC Pulm Med; 2022 Dec; 22(1):490. PubMed ID: 36582007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review.
    Zhao Z; Gao Y; Xue Q; Gao S; He J
    Target Oncol; 2021 Jul; 16(4):425-434. PubMed ID: 33983556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of chronic obstructive pulmonary disease on the efficacy and safety of neoadjuvant immune checkpoint inhibitors combined with chemotherapy for resectable non-small cell lung cancer: a retrospective cohort study.
    Dong W; Yin Y; Yang S; Liu B; Chen X; Wang L; Su Y; Jiang Y; Shi D; Sun D; Qin J
    BMC Cancer; 2024 Jan; 24(1):153. PubMed ID: 38291354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain metastases and immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis.
    Chen H; Feng Y; Zhou Y; Tao Y; Tang L; Shi Y
    Cancer Immunol Immunother; 2022 Dec; 71(12):3071-3085. PubMed ID: 35648238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Outcomes of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Non-small Cell Lung Cancer and Preexisting Interstitial Lung Diseases: A Systematic Review and Meta-analysis.
    Zhang M; Fan Y; Nie L; Wang G; Sun K; Cheng Y
    Chest; 2022 Jun; 161(6):1675-1686. PubMed ID: 35026298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Ba H; Liu L; Peng Q; Chen J; Zhu YD
    BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Value of Perioperative Immunotherapy for Non-Small Cell Lung Cancer: A Pool- and Meta-Analysis.
    Wu Y; Hu L; Zhang S; Zhang H
    Technol Cancer Res Treat; 2024; 23():15330338241258164. PubMed ID: 38872482
    [No Abstract]   [Full Text] [Related]  

  • 13. Prognosis stratification of cancer patients treated with immune checkpoint inhibitors through lung immune prognostic index: a meta-analysis and systematic review.
    Guo Y; Pan Y; Wan J; Gong B; Li Y; Kan X; Zheng C
    BMC Cancer; 2024 Apr; 24(1):523. PubMed ID: 38664760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review and meta-analysis.
    Jiang J; Wang Y; Gao Y; Sugimura H; Minervini F; Uchino J; Halmos B; Yendamuri S; Velotta JB; Li M
    Transl Lung Cancer Res; 2022 Feb; 11(2):277-294. PubMed ID: 35280319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, safety, and survival of neoadjuvant immunochemotherapy in operable non-small cell lung cancer: a systematic review and meta-analysis.
    Zheng Y; Feng B; Chen J; You L
    Front Immunol; 2023; 14():1273220. PubMed ID: 38106421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term outcome of neoadjuvant immunotherapy and chemotherapy in non-small cell lung cancer: A systematic review and meta-analysis.
    Zhang C; Hong HZ; Wu YL; Zhong WZ
    JTCVS Open; 2021 Dec; 8():588-607. PubMed ID: 36004199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The landscape of immune checkpoint inhibitor therapy in advanced lung cancer.
    Wang C; Li J; Zhang Q; Wu J; Xiao Y; Song L; Gong H; Li Y
    BMC Cancer; 2021 Aug; 21(1):968. PubMed ID: 34454455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer patients of different age groups: a meta-analysis.
    Zheng SY; Cui HJ; Duan H; Peng YM; Li Q; Sun CY; Zhang JY; Shen W; Zhang X; Tan K; Jiang X
    Clin Transl Oncol; 2020 Jul; 22(7):1146-1154. PubMed ID: 31748961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II-III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial.
    Zhu X; Sun L; Song N; He W; Xie B; Hu J; Zhang J; Yang J; Dai J; Bian D; Xia H; Sun F; Xiong A; Luo J; Zhang L; Yu H; Liu M; Liu H; Wang H; Zhang H; Chen C; Wu C; Duan L; Zhu Y; Zhang P; Jiang G
    BMC Med; 2022 Dec; 20(1):493. PubMed ID: 36581917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immune-related Adverse Events Induced by ICIs in Advanced NSCLC:
A Meta-analysis and Systematic Review].
    Qin Q; Wang J; Wang H
    Zhongguo Fei Ai Za Zhi; 2020 Sep; 23(9):772-791. PubMed ID: 32752580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.